Star Therapeutics reported phase 1/2 data for VGA039, an anti‑bleeding antibody for a common bleeding disorder, showing substantial reductions in bleeding rates after once‑monthly injection. The company has started dosing in a pivotal phase 3 trial and is weighing options to raise capital, including a possible IPO. Investigators presented the early efficacy and safety data at ASH and Star outlined next steps to complete a larger trial. VGA039’s monthly dosing profile contrasts with current management strategies and supports the antibody's development as a potentially more convenient prophylactic therapy.